DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF CTLA4IG IN PATIENTS WITH PSORIASIS

这项II期研究是一项多中心、随机、安慰剂对照的研究 试验旨在评估安全性，药代动力学，药效学， 牛血清白蛋白-188667(CTLA4Ig)的免疫原性和生物学活性 患有寻常型牛皮癣。符合条件的患者将有稳定的斑块 银屑病病程超过六个月，且至少累及 10%的身体表面积(BSA)，并且至少有一项标准不合格 抗银屑病治疗的毒性和/或无效。信息来自 这项研究将用于制定分阶段给药计划 III在这一患者群体中进行研究。

This Phase II study is a multi-center, randomized, placebo-controlled trial designed to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and biologic activity of BMS-188667 (CTLA4Ig) in patients with psoriasis vulgaris. Eligable patients will have stable plaque psoriasis of greater than six months duration, and involvement of at least 10% body surface area (BSA), and will have failed at least one standard anti-psoriatic therapy for toxicity and/or inefficacy. Information from this study will be used in the development of dosing schedules in Phase III studies in this patient population.